Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline

被引:122
作者
Huddleston, Heather [1 ]
Jungheim, Emily
Tatpati, Laura
Owen, Carter
Penzias, Alan
Bendikson, Kristin
Butts, Samantha
Coutifaris, Christos
Falcone, Tommaso
Fossum, Gregory
Gitlin, Susan
Gracia, Clarisa
Hansen, Karl
La Barbera, Andrew
Mersereau, Jennifer
Odem, Randall
Paulson, Richard
Pfeifer, Samantha
Pisarska, Margareta
Rebar, Robert
Reindollar, Richard
Rosen, Mitchell
Sandlow, Jay
Vernon, Michael
机构
[1] Amer Soc Reprod Med, 1209 Montgomery Hwy, Birmingham, AL 35216 USA
关键词
CLOMIPHENE-RESISTANT WOMEN; RANDOMIZED CONTROLLED-TRIAL; LIVE-BIRTH-RATES; DOUBLE-BLIND; PREGNANCY RATES; INSULIN-RESISTANCE; METABOLIC PROFILES; NONOBESE WOMEN; CITRATE; PLACEBO;
D O I
10.1016/j.fertnstert.2017.06.026
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Metformin alone compared with placebo increases the ovulation rate in women with polycystic ovary syndrome (PCOS) but should not be used as first-line therapy for anovulation because oral ovulation induction agents such as clomiphene citrate or letrozole alone are much more effective in increasing ovulation, pregnancy, and live-birth rates in women with PCOS. There is fair evidence that metformin alone does not increase rates of miscarriage when stopped at the initiation of pregnancy and insufficient evidence that metformin in combination with other agents used to induce ovulation increases live-birth rates. (C) 2017 by American Society for Reproductive Medicine.
引用
收藏
页码:426 / 441
页数:16
相关论文
共 81 条